Celgene Corporation (CELG) Shares Bought by Community Bank & Trust Waco Texas
Community Bank & Trust Waco Texas boosted its stake in shares of Celgene Corporation (NASDAQ:CELG) by 1.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,822 shares of the biopharmaceutical company’s stock after purchasing an additional 373 shares during the quarter. Celgene Corporation accounts for approximately 1.4% of Community Bank & Trust Waco Texas’ holdings, making the stock its 22nd biggest position. Community Bank & Trust Waco Texas’ holdings in Celgene Corporation were worth $2,964,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in CELG. Harel Insurance Investments & Financial Services Ltd. bought a new stake in Celgene Corporation in the 1st quarter valued at $118,000. Motco increased its holdings in Celgene Corporation by 19.3% in the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 159 shares during the period. Penserra Capital Management LLC bought a new stake in Celgene Corporation in the 2nd quarter valued at $129,000. Acropolis Investment Management LLC bought a new stake in Celgene Corporation in the 2nd quarter valued at $144,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in Celgene Corporation by 47.5% in the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 380 shares during the period. Hedge funds and other institutional investors own 78.92% of the company’s stock.
In related news, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the sale, the director now directly owns 85,551 shares in the company, valued at approximately $12,110,599.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ernest Mario sold 18,506 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the sale, the director now owns 69,424 shares in the company, valued at $9,061,220.48. The disclosure for this sale can be found here. Insiders sold a total of 38,733 shares of company stock worth $5,259,359 over the last quarter. 0.95% of the stock is currently owned by corporate insiders.
WARNING: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/11/08/celgene-corporation-celg-shares-bought-by-community-bank-trust-waco-texas.html.
Shares of Celgene Corporation (NASDAQ:CELG) opened at $102.33 on Wednesday. The firm has a market cap of $80,022.90, a P/E ratio of 15.88, a P/E/G ratio of 0.78 and a beta of 1.79. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene Corporation has a 52-week low of $94.55 and a 52-week high of $147.17.
Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. Celgene Corporation’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period last year, the company posted $1.58 EPS. research analysts predict that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.
Several brokerages have issued reports on CELG. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $175.00 price target (up previously from $148.00) on shares of Celgene Corporation in a report on Monday, July 31st. Cantor Fitzgerald set a $160.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, July 27th. William Blair reaffirmed an “outperform” rating on shares of Celgene Corporation in a report on Friday, October 20th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $160.00 target price (up previously from $152.00) on shares of Celgene Corporation in a report on Friday, July 28th. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $156.00 target price on shares of Celgene Corporation in a report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $139.64.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.